🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#GU25. Mevrometostat, an EZH2 inhibitor plus ENZA vs ENZA in mCRPC, Abi and taxane (50%) pretreated pts: Combo, ⬆️ rPFS by 8 months!! Increased GI toxicity and alopecia but generally manageable. MEVRO clinical program to start in Greece soon. Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics ΕΛΛΟΚ OncoAlert

Best Q&A session ever in #GU25. Matt Galsky Tom Powles Elizabeth Plimack MD Cora Sternberg arguing over best treatment approach in localized Bladder cancer upon presentation of NIAGARA and CM274 updated results!! Excellent discussion from Elizabeth Plimack MD. Petros Grivas OncoAlert

Join tombal & me in a fun virtual educational webinar! Link: us02web.zoom.us/webinar/regist… Mirrors of Medicine Marinos Tsiatas MikaLion ANASTASIOS KYRIAZOGLOU Ζenia Saridaki Daniele Raggi Laura Marandino Amalya Sargsyan Myrto K. Moutafi Evangelia (Elina) Vlachou, MD Bernadett Szabados Umang Swami Abhishek Tripathi OncoAlert

The last castle has fallen. First positive phase III IO clinical trial in ovarian cancer!!!! Could PARPi resistance prime for IO efficacy? IO-ADCs combos seem the next rationale apprach for this disease setting. OncoAlert ESGO ΕΟΠΕ merck.com/news/merck-ann…

It could be the sandy beach of a Greek island as well, but it’s just the Golden Coast at Lake Michigan. #ASCO2025

Despite these approaches already obsolete by EV-Pembro, CM-901 Ipi-Nivo vs Gem Carbo in Cis- ineligible was STATISTICALLY negative but with clinical meaningful benefit. Almost 30% discontinued IO due to toxicity. #ASCO25 ASCO OncoAlert Petros Grivas

Excellent news for EV-P responders! In EV-302 median DoR 23 months, hope for cure for those in CR ( 3 out of 4) remaining CR long term!! Very informative data by Shilpa Gupta! Congrats to Jacqueline T. Brown, MD for excellent and inspiring discussion. #ASCO25 UroToday.com OncoAlert eeoogek.gr

CAR-T cells therapy makes initial steps towards RCC therapeutic algorithm. An anti-CD70 allogeneic Car-T demonstrated 25% ORR limited to high expressing CD70 tumours. Some responses durable! ASCO UroToday.com VuMedi Oncology OncoAlert . Exciting new data #ASCO25

Belzutifan revolutionised VHL treatment. Dr Narayan presented extended follow up data indicating control of the disease with limited interventions for the majority of the patients. Management of the few progressors remain tricky. #ASCO25 UroToday.com ASCO

SERENA study addition of camizestran at ctDNA positivity for ESR1 mutation increased PFS. No solid conclusions for the clinical importance due to study design. Excellent commentary for the negative implications of this early intervention tactic. Anna Svarna OncoAlert #ASCo25

No one denies that Nivo-IPi in CM-214 has offered the highest OS rate in 1st line RCC.

1/2TRUST trial announced negative for OS at #ASCO25!! Statistical significant ⬆️ PFS with primary surgery. Effect most striking among those with R0 resections. Conclusions: - Reassure high quality surgery - No major change in clinical practice OncoAlert ESGO ASCO

2/2 TRUST study. No molecular data available. PFS increase does not translate into OS benefit. Maybe a signal with longer follow-up? - Biology of the disease determines survival more than surgery.

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, Amgen 🧪🔬🧬 science team and above all our pts

Congratulations Giannis Mountzios for leading this practice changing trial!!

Drs Sonneveld,Terpos,and Gavriatopoulou presenting at EHA 2025 the new EHA EMN guidelines for the treatment of multiple myeloma

Dr. Antonio Gonzalez Martin set perfectly the stage for treatment evolution in HRP patients. Very limited benefit from current CT and maintenance therapy options. Are we ready to explore non chemotherapy regimens for HRP pts? #ESMOGyn25 ESMO - Eur. Oncology OncoAlert

⁦Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics⁩ Team at #ESMOGynae25 with our Head ⁦Thanos Dimopoulos⁩. We presented 3 posters from our clinical research in ovarian cancer. ⁦Magdalini Migkou⁩ ⁦Maria Kaparelou⁩ ⁦JohnNtan⁩ Katerina Aravantinou. ⁦⁦OncoAlert⁩ ⁦VuMedi Oncology⁩